Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
group_4_presentation_3_-_effects_of_marijuana_on_the_brain [2017/04/07 20:31] cardozs |
group_4_presentation_3_-_effects_of_marijuana_on_the_brain [2018/01/25 15:18] (current) |
||
|---|---|---|---|
| Line 17: | Line 17: | ||
| =====CANNABIS CONSUMPTION===== | =====CANNABIS CONSUMPTION===== | ||
| + | Marijuana can be consumed in various ways ranging from liquid tinctures to dermal patches and oral sprays. Firstly, liquid tinctures are extracts taken from the marijuana plant that are taken orally; as well as oral sprays which could also be administered orally (Cohen & Rudick, 2007). Dermal patches are effective due to the lipophilic property of marijuana, which allows it to be readily dissolved in a fat-soluble substance and penetrate the cell membrane (Rosenthal & Newhart, 2002). The most common way of consuming marijuana is through smoking, vaporizing and eating edibles. Marijuana is often consumed by packing the dried buds into rolling paper, cigars, pipes, or bongs. Also, many prefer to eat marijuana edibles such as, weed brownies and cookies. Other less common methods of consumption include, capsules and lozenges (Rosenthal & Newhart, 2002). | ||
| ---- | ---- | ||
| =====CANNABIS USAGE===== | =====CANNABIS USAGE===== | ||
| ====MEDICINAL==== | ====MEDICINAL==== | ||
| + | |||
| + | Marijuana has three prominent usages, medicinal, spiritual and recreational. It is often quite difficult for scientists to study potential medicinal marijuana uses since it is difficult to obtain permission for human medical trials (Richard & Paul, nd). Furthermore, marijuana is currently classified as a schedule 2 substance by the federal government, making it even tougher to obtain permission (Hoffmann & Weber, 2010). In addition, far more studies regarding the potential harmful effects of marijuana have been conducted and only very minimal (6%) have been conducted studying its potential benefits (Gupta, 2013). Many studies focusing on the medicinal use of marijuana have shown varying results and despite little research on marijuana per se, it is important to note this does not imply that marijuana has no medicinal purposes. | ||
| + | |||
| + | However, few case studies and research has led to promising results for potential medicinal uses of marijuana. Firstly, marijuana can be considered during chemotherapy to alleviate common side effects such as vomiting and nausea (Murnion, 2015). Individuals with HIV/AIDS may also use marijuana for similar reasons along with improving their appetite. Marijuana has also been somewhat effective in treating chronic pain and muscle spasms, including pain from neuropathy that may be caused due to fibromyalgia and rheumatoid arthritis (Murnion, 2015). Marijuana has also shown limited evidence in treating neurological problems such as, multiple sclerosis and epilepsy. In epilepsy specifically, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have shown to give patients relief from cases of spasticity (Murnion, 2015). In addition, some studies have shown marijuana has significantly improved tics in patients suffering from Tourette syndrome. Marijuana can also act as a supplementary means of treatment in individuals suffering from anorexia, arthritis, glaucoma and migraines (Richard & Paul, nd). | ||
| + | |||
| + | Although minimal research has been conducted on cannabinoids and its use in treatment of cancer, cannabinoids have displayed anti-cancer effects in various laboratory experiments. There is ongoing research being conducted to explore different medicinal properties of marijuana. There has been extensive focus on marijuana’s effect on dementia, diabetes, epilepsy, glaucoma, and Tourette syndrome. Cannabinoids have been hypothesized to relieve some of the symptoms associated with Alzheimer’s Disease and may assist in slowing cell damage in diabetes mellitus type 1 (Caulkins, Kilmer, & Kleiman, 2016) | ||
| + | . | ||
| ---- | ---- | ||
| ====SPIRITUAL==== | ====SPIRITUAL==== | ||
| + | |||
| + | Marijuana has had a long history of spiritual use and both historically and presently has been viewed as an entheogenic. To elaborate, marijuana has been used to reach a stage of enlightenment, connection, and nirvana. Despite its rich historical use, many religions have opposing stances on marijuana, but those in support have associated the psychoactive effects that marijuana may produce with an intense spiritual experience (Bello, 2007). | ||
| ---- | ---- | ||
| ====RECREATIONAL==== | ====RECREATIONAL==== | ||
| + | |||
| + | The use of a psychoactive drug to alter one’s mind state, modify emotions, cognitions, and perceptions is often described as recreational usage. Marijuana has been long used as a recreational drug due its psychoactive effects (Bello, 2007). Today, people use marijuana for several activities and occasions, including but not limited to (Osborne & Fogel, 2008) : | ||
| + | |||
| + | * Relaxing and Concentrating | ||
| + | * Making everyday activities more enjoyable | ||
| + | * Eating | ||
| + | * Listening to music | ||
| + | * Socializing | ||
| + | * Watching movies | ||
| + | * Playing sports | ||
| + | * Having Sex | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| ---- | ---- | ||
| Line 40: | Line 70: | ||
| In Canada, as in many other countries, marijuana is the most commonly used illicit drug (Statistics Canada, 2013). | In Canada, as in many other countries, marijuana is the most commonly used illicit drug (Statistics Canada, 2013). | ||
| - | <box 80% round | >{{:rsz_1231324reqwf.png|}} </box|Figure ##: Estimated prevalence (proportion) of cannabis dependence by age, sex and region, 2010. (Degenhard et al, 2013)> | + | <box 80% round | >{{:rsz_1231324reqwf.png|}} </box|Figure 2: Estimated prevalence (proportion) of cannabis dependence by age, sex and region, 2010. (Degenhard et al, 2013)> |
| Throughout the world the prevalence was higher in males than females, resulting in an average male:female sex ratio of 1.8 (Degenhard et al, 2013). Prevalence peaks worldwide in the 20-24 years age group at between and then steadily decreasing after that age group thereafter (Degenhard et al, 2013). | Throughout the world the prevalence was higher in males than females, resulting in an average male:female sex ratio of 1.8 (Degenhard et al, 2013). Prevalence peaks worldwide in the 20-24 years age group at between and then steadily decreasing after that age group thereafter (Degenhard et al, 2013). | ||
| - | <box 50% round | >{{:rsz_1journalpone0076635g002.png|}} </box|Figure ##: Pooled regional prevalence of cannabis dependence, 2010. | + | <box 50% round | >{{:rsz_1journalpone0076635g002.png|}} </box|Figure 3: Pooled regional prevalence of cannabis dependence, 2010. |
| Note. Prevalence estimates were standardised by population age and sex; AP-HI: Asia Pacific, High Income, As-C: Asia Central, AS-E: Asia East, AS-S: Asia South, A-SE: Asia Southeast, Aus: Australasia, Caribb: Caribbean, Eur-C: Europe Central, Eur-E: Europe Eastern, Eur-W: Europe Western, LA-An: Latin America, Andean, LA-C: Latin America, Central, LA-Sth: Latin America, Southern, LA-Trop: Latin America, Tropical, Nafr-ME: North Africa/Middle East, Nam-HI: North America, High Income, Oc: Oceania, SSA-C: Sub-Saharan Africa, Central, SSA-E: Sub-Saharan Africa, East, SSA-S: Sub-Saharan Africa Southern, SSA-W: Sub-Saharan Africa, West. (Degenhard et al, 2013)> | Note. Prevalence estimates were standardised by population age and sex; AP-HI: Asia Pacific, High Income, As-C: Asia Central, AS-E: Asia East, AS-S: Asia South, A-SE: Asia Southeast, Aus: Australasia, Caribb: Caribbean, Eur-C: Europe Central, Eur-E: Europe Eastern, Eur-W: Europe Western, LA-An: Latin America, Andean, LA-C: Latin America, Central, LA-Sth: Latin America, Southern, LA-Trop: Latin America, Tropical, Nafr-ME: North Africa/Middle East, Nam-HI: North America, High Income, Oc: Oceania, SSA-C: Sub-Saharan Africa, Central, SSA-E: Sub-Saharan Africa, East, SSA-S: Sub-Saharan Africa Southern, SSA-W: Sub-Saharan Africa, West. (Degenhard et al, 2013)> | ||
| Prevalence in high income regions was much higher than that in low to middle income regions and the global average (Degenhard et al, 2013). Cannabis dependence in Australasia is about 8 times higher than prevalence in Sub-Saharan Africa, West (Degenhard et al, 2013). | Prevalence in high income regions was much higher than that in low to middle income regions and the global average (Degenhard et al, 2013). Cannabis dependence in Australasia is about 8 times higher than prevalence in Sub-Saharan Africa, West (Degenhard et al, 2013). | ||
| - | <box 50% round | >{{:rsz_journalpone0076635g004.png|}}</box|Figure ##: Country-level DALYs per 100,000 population for cannabis dependence, age-standardised, for 2010. | + | <box 50% round | >{{:rsz_journalpone0076635g004.png|}}</box|Figure 4: Country-level DALYs per 100,000 population for cannabis dependence, age-standardised, for 2010. |
| Note. Low: shows countries with statistically lower DALY rates than global mean; Middle: Shows countries with DALY rates that are not statistically different to global mean; High: Shows countries with statistically higher DALY rates than global mean. (Degenhard et al, 2013)> | Note. Low: shows countries with statistically lower DALY rates than global mean; Middle: Shows countries with DALY rates that are not statistically different to global mean; High: Shows countries with statistically higher DALY rates than global mean. (Degenhard et al, 2013)> | ||
| Line 135: | Line 165: | ||
| Arnone, D., Barrick, T. R., Chengappa, S., Mackay, C. E., Clark, C. A., & Abou-Saleh, M. T. (2008). Corpus callosum damage in heavy marijuana use: preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. Neuroimage, 41(3), 1067-1074. | Arnone, D., Barrick, T. R., Chengappa, S., Mackay, C. E., Clark, C. A., & Abou-Saleh, M. T. (2008). Corpus callosum damage in heavy marijuana use: preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. Neuroimage, 41(3), 1067-1074. | ||
| + | |||
| + | Bello, J. (2007). The Benefits of Marijuana: Physical, Psychological and Spiritual. Lifeservices Press. | ||
| + | |||
| Block, R. I., O'leary, D. S., Ehrhardt, J. C., Augustinack, J. C., Ghoneim, M. M., Arndt, S., & Hall, J. A. (2000). Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport, 11(3), 491-496. | Block, R. I., O'leary, D. S., Ehrhardt, J. C., Augustinack, J. C., Ghoneim, M. M., Arndt, S., & Hall, J. A. (2000). Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport, 11(3), 491-496. | ||
| Line 146: | Line 179: | ||
| Brock, Tom. "CANNABINOID SIGNALING: THE ORIGINAL RETROGRADE SIGNALING PATHWAY". Caymanchem.com. N.p., 2008. Web. 2 Apr. 2017. | Brock, Tom. "CANNABINOID SIGNALING: THE ORIGINAL RETROGRADE SIGNALING PATHWAY". Caymanchem.com. N.p., 2008. Web. 2 Apr. 2017. | ||
| + | |||
| + | Caulkins, J. P., Kilmer, B., & Kleiman, M. A. (2016). Marijuana Legalization: What Everyone Needs to Know?. Oxford University Press. | ||
| + | |||
| + | Cohen, J. A., & Rudick, R. A. (Eds.). (2007). Multiple sclerosis therapeutics. CRC Press. | ||
| Deem, R. (2013). The Medical "Benefits" of Smoking Marijuana (Cannabis): a Review of the Current Scientific Literatureby Rich Deem. Retrieved April 01, 2017, from http://www.godandscience.org/doctrine/medical_marijuana_review.html | Deem, R. (2013). The Medical "Benefits" of Smoking Marijuana (Cannabis): a Review of the Current Scientific Literatureby Rich Deem. Retrieved April 01, 2017, from http://www.godandscience.org/doctrine/medical_marijuana_review.html | ||
| Line 156: | Line 193: | ||
| Foltin, R. W., Fischman, M. W., & Byrne, M. F. (1988). Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite, 11(1), 1-14. | Foltin, R. W., Fischman, M. W., & Byrne, M. F. (1988). Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite, 11(1), 1-14. | ||
| + | |||
| + | Gupta, S. (2013). Why I changed my mind on weed. CNN. com, 9. | ||
| Hendershot, C. S., Magnan, R. E., & Bryan, A. D. (2010). Associations of marijuana use and sex-related marijuana expectancies with HIV/STD risk behavior in high-risk adolescents. Psychology of Addictive Behaviors, 24(3), 404. | Hendershot, C. S., Magnan, R. E., & Bryan, A. D. (2010). Associations of marijuana use and sex-related marijuana expectancies with HIV/STD risk behavior in high-risk adolescents. Psychology of Addictive Behaviors, 24(3), 404. | ||
| + | |||
| + | Hoffmann, D. E., & Weber, E. (2010). Medical marijuana and the law. New England Journal of Medicine, 362(16), 1453-1457. | ||
| H. (2015, September 17). The Effects Of Weed On Your Health. Retrieved April 01, 2017, from http://herb.co/2015/09/17/the-effects-of-weed-on-your-health/ | H. (2015, September 17). The Effects Of Weed On Your Health. Retrieved April 01, 2017, from http://herb.co/2015/09/17/the-effects-of-weed-on-your-health/ | ||
| Line 169: | Line 210: | ||
| Lotan, I., Treves, T. A., Roditi, Y., & Djaldetti, R. (2014). Cannabis (Medical Marijuana) Treatment for Motor and Non–Motor Symptoms of Parkinson Disease: An Open-Label Observational Study. Clinical neuropharmacology, 37(2), 41-44. | Lotan, I., Treves, T. A., Roditi, Y., & Djaldetti, R. (2014). Cannabis (Medical Marijuana) Treatment for Motor and Non–Motor Symptoms of Parkinson Disease: An Open-Label Observational Study. Clinical neuropharmacology, 37(2), 41-44. | ||
| + | |||
| + | Murnion, B. (2015). Medicinal cannabis. Australian prescriber, 38(6), 212. | ||
| Osborne, G. B., & Fogel, C. (2008). Understanding the motivations for recreational marijuana use among adult Canadians. Substance use & misuse, 43(3-4), 539-572. | Osborne, G. B., & Fogel, C. (2008). Understanding the motivations for recreational marijuana use among adult Canadians. Substance use & misuse, 43(3-4), 539-572. | ||
| Line 177: | Line 220: | ||
| Short- & Long-Term Effects of Marijuana - Negative Side Effects of Weed - Drug-Free World. (n.d.). Retrieved April 01, 2017, from http://www.drugfreeworld.org/drugfacts/marijuana/short-and-long-term-effects.html | Short- & Long-Term Effects of Marijuana - Negative Side Effects of Weed - Drug-Free World. (n.d.). Retrieved April 01, 2017, from http://www.drugfreeworld.org/drugfacts/marijuana/short-and-long-term-effects.html | ||
| + | |||
| + | Richard, O. N., & Paul, O. B. Medical Marijuana: Basic Scientific View. | ||
| + | |||
| + | Rosenthal, E., & Newhart, S. (2002). Marijuana Gold: Trash to Stash. Ed Rosenthal. | ||
| "The Science Of Marijuana: How THC Affects The Brain". Headsup.scholastic.com. N.p., 2011. Web. 2 Apr. 2017. | "The Science Of Marijuana: How THC Affects The Brain". Headsup.scholastic.com. N.p., 2011. Web. 2 Apr. 2017. | ||
